Long-term relationship launching this month with two commercial programs and a clinical research study at health plans across the US
Madison, Wisconsin and New York, New York – April 18, 2016 – Propeller Health, the leading digital health solution for respiratory medicine, and AMC Health, the leading provider of proven remote patient monitoring and engagement solutions that are exclusively endorsed by the American Hospital Association, today announced a partnership to help patients living with chronic obstructive pulmonary disease (COPD) and asthma better manage their disease and reduce symptoms and hospital visits.
The partnership will bring together Propeller’s expertise in improving medication adherence and predicting and reducing disease exacerbations with AMC Health’s expertise in improving outcomes through enhanced clinical efficiency and care coordination. The multi-year partnership signed in January will launch this month with two commercial programs and a clinical research study investigating adherence barriers at large health plans across the United States. AMC Health will integrate Propeller’s platform into their care management system to complement existing clinical workflows. Propeller and AMC Health are actively recruiting other health plan participation. Together these efforts aim to provide better, more proactive care for COPD and asthma to reduce costly hospital admissions and readmissions.
AMC Health is focused on transforming healthcare delivery across chronic disease through remote patient monitoring and virtual care coordination. The company has proven through multiple studies, which are unprecedented in size and duration, cover various disease states and are published in independent, peer-reviewed publications, that outcomes can be improved significantly through connecting patients to their clinical teams on a real-time basis and expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings.
The new partnership with AMC Health will supplement Propeller’s existing business, and new customers can continue to sign up directly with Propeller or through the new partnership with AMC Health. Propeller has been used by people with chronic respiratory diseases in over 40 commercial programs across the U.S., including major healthcare systems, payers, employers and other organizations. It is compatible with the majority of commonly used inhaler devices including controller and reliever medications. Propeller’s platform is 510(k) cleared to help improve adherence, reduce symptoms, and predict exacerbations in COPD and asthma. Through a combination of inhaler sensors, apps, analytics, personal feedback and education, it passively tracks when and where each patient uses their inhaled medications and can send alerts to patients to prompt medication use and caregivers to highlight patients who are at risk or impaired and may require proactive intervention.
“Our commercial partnership begins with COPD which is a challenging disease to manage, and it becomes increasingly difficult as it progresses. Most COPD patients are also burdened by comorbidities. Our partnership with AMC Health aims to help leading healthcare systems overcome these challenges through a more connected approach to care,” said David Van Sickle, CEO of Propeller. “We are also excited about partnering in asthma including new research made possible through this relationship”.
“Our clinical, technology and analytics expertise enables us to empower patients to confidently manage their health, and connect them to the most appropriate intervention at the right time. This has a significant impact on patients with chronic health issues such as COPD and asthma,” said Nesim Bildirici, president and CEO of AMC Health. “Combining AMC Health’s 13 years of real-time virtual care experience with Propeller’s expertise in improving medication adherence supports improved health outcomes and care management efficiencies that substantially benefit patients and their care teams.”
About Propeller Health
Founded in 2010, Propeller is the leading provider of an FDA-cleared digital health platform that helps reduce the cost of care while delivering better quality of life for individuals with chronic respiratory disease. Propeller provides better engagement, communication, and more insightful and personalized care. Backed by Safeguard Scientifics (NYSE: SFE), Social Capital, California HealthCare Foundation, Kapor Capital and other investors, Propeller has been used by patients with asthma or COPD in over 40 commercial programs across the US at major healthcare systems, payers, employers and other commercial partners. Company recognition includes TEDMED Innovation Showcase, White House Champion of Change, and Bluetooth Breakthrough Product awards. Contact us at email@example.com to discuss how Propeller can empower patients and create value in your organization.
About AMC Health
AMC Health offers an FDA-cleared remote patient engagement solution supporting care program effectiveness, behavior change, and clinical efficiencies for chronic and post-acute populations. AMC Health has proven through multiple studies, which are unprecedented in size and duration, cover various disease states and published in independent, peer-reviewed publications, that outcomes can be improved significantly through connecting patients to their clinical teams on a real-time basis and expanding care beyond the walls of hospitals, doctors’ offices and outpatient settings. The published studies show reduced medical costs and hospital readmissions, improved care management, and 3:1 return on investment, exceeding competitors’ less rigorous customer evaluations. AMC Health’s remote patient monitoring and engagement solutions have earned the exclusive endorsement of the American Hospital Association. AMC Health is headquartered in New York, NY. For more information, visit www.amchealth.com.
Tanya L. Travers